drugset
drugset / Trial / NCT02683889

Use of Acthar in Patients With FSGS That Will be Undergoing Renal Transplantation

NCT02683889 ↗

Phase 3 Completed 15 enrolled University of Colorado, Denver
NaSingle-groupOpen-labelPrevention

Summary

This study will evaluate the use of Acthar in patients to undergo renal transplantation and will measure the rate of FSGS recurrence.

Timeline

Start
2019-02-01
Primary completion
2024-06-06
Completion
2024-06-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Acthar Peptide 80 iu —

Indications

focal segmental glomerulosclerosis